Latest News for: bristol myers squibb

Edit

Bristol Myers Squibb Reports First Quarter Financial Results for 2026 (Bristol-Myers Squibb Company)

Public Technologies 30 Apr 2026
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE ... About Bristol Myers Squibb ... At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Edit

Bristol Myers Squibb Logs Higher Sales, Profit

Wall Street Journal 30 Apr 2026
Bristol Myers Squibb posted higher first-quarter revenue boosted by its portfolio of newer treatments for heart and blood conditions ... .
Edit

Bristol Myers Squibb Reports First Quarter Financial Results for 2026

The Eagle-Tribune 30 Apr 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Apr 30, 2026-- ... .
Edit

Q1 2026 Results Presentation (Bristol-Myers Squibb Company)

Public Technologies 30 Apr 2026
) Q1 2026 Results. April 30, 2026. Not for Product Promotional Use. Q1 2026 Results. Chris Boerner, PhD. Board Chair and ... Bristol-Myers Squibb Company published this content on April 30, 2026, and is solely responsible for the information contained herein.
Edit

Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations

The Call 30 Apr 2026
Biopharmaceutical company Bristol Myers Squibb (NYSE ... Is now the time to buy Bristol-Myers Squibb? Find out by accessing our full research report, it’s free. Bristol-Myers Squibb (BMY) Q1 CY2026 Highlights..
Edit

Bristol Myers Squibb Reports First Quarter Financial Results for 2026 (Form 8-K) (Bristol-Myers Squibb Company)

Public Technologies 30 Apr 2026
) Bristol Myers Squibb Reports First Quarter Financial Results for 2026 ... (PRINCETON, N.J., April 30, 2026) - Bristol Myers Squibb (NYSE ... Bristol Myers Squibb will host a conference call today, Thursday, April 30, 2026, at 8.00 a.m.
Edit

Q1 2026 Results Presentation with Appendix (Bristol-Myers Squibb Company)

Public Technologies 30 Apr 2026
) Q1 2026 Results. April 30, 2026. Not for Product Promotional Use. Q1 2026 Results. Chris Boerner, PhD. Board Chair and ... Bristol-Myers Squibb Company published this content on April 30, 2026, and is solely responsible for the information contained herein.
Edit

Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) (Bristol-Myers Squibb Company)

Public Technologies 30 Apr 2026
) MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ... EXECUTIVE SUMMARY ... Breyanzi ... Bristol-Myers Squibb Company published this content on April 30, 2026, and is solely responsible for the information contained herein.
Edit

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow

The Call 29 Apr 2026
Biopharmaceutical company Bristol Myers Squibb (NYSE ... Bristol-Myers Squibb beat analysts’ revenue expectations last quarter, reporting revenues of $12.5 billion, up 1.3% year on year ... Bristol-Myers Squibb is down 2.6% during the same time .
Edit

Psoriasis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB ...

GetNews 29 Apr 2026
In February 2025, Bristol Myers Squibb (BMS), a US-based pharmaceutical company, announced results from the POETYK PSO long-term extension (LTE) trial evaluating Sotyktu (deucravacitinib) for plaque psoriasis.
Edit

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus ...

Enid News & Eagle 24 Apr 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Apr 24, 2026-- ... .
Edit

Bristol Myers Squibb and Pfizer to Make Eliquis� (apixaban) Available via Mark Cuban Cost Plus ...

Business Wire 24 Apr 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Eliquis--Bristol Myers Squibb and Pfizer to Make Eliquis� (apixaban) Available via Mark Cuban Cost Plus Drug Company ... .
Edit

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

Pharmiweb 24 Apr 2026
Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those ...
Edit

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

PR Newswire 23 Apr 2026
RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE.
Edit

Sjogren's Syndrome Market Analysis Report 2025-2035 Featuring Novartis, Otsuka Pharmaceutical, Nicox, and Bristol Myers Squibb

Nasdaq Globe Newswire 22 Apr 2026
Key players like Novartis and Bristol Myers Squibb are enhancing research efforts ... Key players like Novartis and Bristol Myers Squibb are enhancing research efforts ... .

Article Search

tools
×
×
×
×